Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors.
作者： V J Wiebe , C K Osborne , W L McGuire , M W DeGregorio
DOI: 10.1200/JCO.1992.10.6.990
关键词:
摘要: PURPOSEWe have shown previously that acquired tamoxifen resistance in an vivo experimental model is associated with reduced accumulation, isomerization of trans-4-hydroxytamoxifen, and tamoxifen-stimulated tumor growth. The purpose this study to isolate verify the presence estrogenic metabolites human breast tumors using high-performance liquid chromatography (HPLC) mass-spectrometry (MS) techniques.PATIENTS AND METHODSIn present study, we used HPLC MS identify samples excised from athymic nude mice isolated patients receiving adjuvant therapy.RESULTSWe identified metabolite E, a known tamoxifen, tamoxifen-resistant MCF-7 implanted mice, as well clinical resistance. Additionally, separated another metabolite, bisphenol, by HPLC, wa...
elsevier.com
sci-hub.se 参考文章(10)
S M Langan-Fahey, R McCague, C S Murphy, V C Jordan, Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro. Molecular Pharmacology. ,vol. 38, pp. 737- 743 ,(1990)
David W. Robertson, John A. Katzenellenbogen, Deborah J. Long, Ellen A. Rorke, Benita S. Katzenellenbogen, Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen Journal of Steroid Biochemistry. ,vol. 16, pp. 1- 13 ,(1982) , 10.1016/0022-4731(82)90137-6
H.K. Adam, E.J. Douglas, J.V. Kemp, The metabolism of tamoxifen in humans Biochemical Pharmacology. ,vol. 28, pp. 145- 147 ,(1979) , 10.1016/0006-2952(79)90283-1
SAMUEL G. TAYLOR, Combination Chemotherapy Compared to Tamoxifen as Initial Therapy for Stage IV Breast Cancer in Elderly Women Annals of Internal Medicine. ,vol. 104, pp. 455- 461 ,(1986) , 10.7326/0003-4819-104-4-455
C. Murphy, T. Fotsis, P. Pantzar, H. Adlercreut, F. Martin, Analysis of tamoxifen and its metabolites in human plasma by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM). Journal of Steroid Biochemistry. ,vol. 26, pp. 547- 555 ,(1987) , 10.1016/0022-4731(87)90006-9
John V. Kemp, Hugh K. Adam, Alan E. Wakeling, Roger Slater, Identification and biological activity of tamoxifen metabolites in human serum Biochemical Pharmacology. ,vol. 32, pp. 2045- 2052 ,(1983) , 10.1016/0006-2952(83)90425-2
B.J.A. Furr, V.C. Jordan, The pharmacology and clinical uses of tamoxifen Pharmacology & Therapeutics. ,vol. 25, pp. 127- 205 ,(1984) , 10.1016/0163-7258(84)90043-3
Stewart D. Lyman, V. Craig Jordan, Metabolism of tamoxifen and its uterotrophic activity Biochemical Pharmacology. ,vol. 34, pp. 2787- 2794 ,(1985) , 10.1016/0006-2952(85)90580-5
Richard R. Bain, M. Amparo Santos, Raymond R. Brown, Barbara Gosden, V. Craig Jordan, Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. Cancer Research. ,vol. 43, pp. 1446- 1450 ,(1983)
Oscar A. Lea, Per M. Ueland, Einar Solheim, Steinar Lundgren, Ernst A. Lien, Stener Kvinnsland, Distribution of 4-Hydroxy-N-desmethyltamoxifen and Other Tamoxifen Metabolites in Human Biological Fluids during Tamoxifen Treatment Cancer Research. ,vol. 49, pp. 2175- 2183 ,(1989)